Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of LY01022 vs Zoladex in Prostate Cancer
NCT05856630Phase 1Unknown
- Sponsor
- Luye Pharma Group
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of goserelin acetate extended-release microspheres LY01022 in prostate cancer (PCa) (2 arms), sponsored by Luye Pharma Group. Primary endpoint: Changes in plasma goserelin concentration. Status: unknown.
02
Drugs
goserelin acetate extended-release microspheres LY01022
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05856630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05856630.